BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9596700)

  • 1. Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.
    Laferriere CA; Sood RK; de Muys JM; Michon F; Jennings HJ
    Infect Immun; 1998 Jun; 66(6):2441-6. PubMed ID: 9596700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.
    Safari D; Dekker HA; Joosten JA; Michalik D; de Souza AC; Adamo R; Lahmann M; Sundgren A; Oscarson S; Kamerling JP; Snippe H
    Infect Immun; 2008 Oct; 76(10):4615-23. PubMed ID: 18678667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity.
    Laferrière CA; Sood RK; de Muys JM; Michon F; Jennings HJ
    Vaccine; 1997 Feb; 15(2):179-86. PubMed ID: 9066036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.
    Alonso de Velasco E; Verheul AF; van Steijn AM; Dekker HA; Feldman RG; Fernández IM; Kamerling JP; Vliegenthart JF; Verhoef J; Snippe H
    Infect Immun; 1994 Mar; 62(3):799-808. PubMed ID: 7509318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.
    Mawas F; Niggemann J; Jones C; Corbel MJ; Kamerling JP; Vliegenthart JF
    Infect Immun; 2002 Sep; 70(9):5107-14. PubMed ID: 12183560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immune response to group B streptococcus type III capsular polysaccharide is directed to the -Glc-GlcNAc-Gal- backbone epitope.
    Safari D; Dekker HA; Rijkers GT; van der Ende A; Kamerling JP; Snippe H
    Glycoconj J; 2011 Dec; 28(8-9):557-62. PubMed ID: 21984010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae.
    Nahm MH; Olander JV; Magyarlaki M
    J Infect Dis; 1997 Sep; 176(3):698-703. PubMed ID: 9291318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques.
    McNeely TB; Staub JM; Rusk CM; Blum MJ; Donnelly JJ
    Infect Immun; 1998 Aug; 66(8):3705-10. PubMed ID: 9673252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide.
    Wessels MR; Kasper DL
    J Exp Med; 1989 Jun; 169(6):2121-31. PubMed ID: 2471773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine.
    Vidarsson G; Sigurdardottir ST; Gudnason T; Kjartansson S; Kristinsson KG; Ingolfsdottir G; Jonsson S; Valdimarsson H; Schiffman G; Schneerson R; Jonsdottir I
    Infect Immun; 1998 Jun; 66(6):2866-70. PubMed ID: 9596761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine.
    Safari D; Marradi M; Chiodo F; Th Dekker HA; Shan Y; Adamo R; Oscarson S; Rijkers GT; Lahmann M; Kamerling JP; Penadés S; Snippe H
    Nanomedicine (Lond); 2012 May; 7(5):651-62. PubMed ID: 22630149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies.
    Jansen WT; Gootjes J; Zelle M; Madore DV; Verhoef J; Snippe H; Verheul AF
    Clin Diagn Lab Immunol; 1998 Sep; 5(5):703-10. PubMed ID: 9729539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.
    Poolman J; Frasch C; Nurkka A; Käyhty H; Biemans R; Schuerman L
    Clin Vaccine Immunol; 2011 Feb; 18(2):327-36. PubMed ID: 21123523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
    Madoff LC; Paoletti LC; Tai JY; Kasper DL
    J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody- and cell-mediated immune responses to a synthetic oligosaccharide conjugate vaccine after booster immunization.
    Safari D; Dekker HA; de Jong B; Rijkers GT; Kamerling JP; Snippe H
    Vaccine; 2011 Sep; 29(38):6498-504. PubMed ID: 21767596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
    Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
    Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an opsonin inhibition assay for evaluation of complex polysaccharide protective epitopes.
    McNeely T; Luo S; Manger W; Herber W; Schofield T; Tan C; Newman K; Sadoff J; Donnelly J; Cross A
    Vaccine; 2006 Mar; 24(11):1941-8. PubMed ID: 16307833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide--protein conjugate vaccine is decreased by admixture of high doses of free saccharide.
    Peeters CC; Tenbergen-Meekes AM; Poolman JT; Zegers BJ; Rijkers GT
    Vaccine; 1992; 10(12):833-40. PubMed ID: 1455909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC; Wessels MR; Michon F; DiFabio J; Jennings HJ; Kasper DL
    Infect Immun; 1992 Oct; 60(10):4009-14. PubMed ID: 1398913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
    J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.